Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, Wolchok, JD, Solit DB, Rosen N, Abdel-Wahab O, Levine RL, Chapman PB. Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. N Engl J Med. 2012 Dec 13;367(24):2316-21.

Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, Mollica L, Li J, Viale A, Heguy A, Hassimi M, Socci N, Bhatt PK, Gonen M, Mason CE, Melnick A, Godley LA, Brennan CW, Abdel-Wahab O* (co-last author), Levine RL. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012 Nov;44(11):1179-81.

Abdel-Wahab O, Adli M, Lafave LM, Gao J, Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, Perna F, Zhao X, Taylor JE, Park CY, Carroll M, Melnick A, Nimer SD, Jaffe JD, Aifantis I, Bernstein BE, Levine RL. ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression. Cancer Cell. 2012 Aug 14;22(2):180-93.

Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya MS, Kirkpatrick DS, Pham VC, Lill JR, Bakalarski CE, Wu J, Phu L, Katavolos P, LaFave LM, Abdel-Wahab O, Modrusan Z, Seshagiri S, Dong K, Lin Z, Balazs M, Suriben R, Newton K, Hymowitz S, Garcia-Manero G, Martin F, Levine RL, Dixit VM. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science. 2012 Sep 21;337(6101):1541-6.

Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012 Sep 20;30(27):3376-82.

Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Sep 6;489(7414):155-9.

Patel, JP, Gonen, M, Figueroa, M, Fernandez, HF, Zhuoxin, S, Van Vlierberghe, P, Dolgalev, I, Thomas, S, Aminova, O, Huberman, K, Cheng, J, Viale, A, Socci, ND, Heguy, A, Cherry, A, Vance, G, Higgins, R, Ketterling, R, Gallagher, R, Litzow, M, van den Brink, M, Lazarus, H, Rowe, J, Luger, S, Ferrando, AF, Paietta, E, Tallman, MS, Melnick, AM, Abdel-Wahab, O (co-last author), and Levine, RL. Prognostic and therapeutic relevance of integrated genetic profiling in AML. N Engl J Med. 2012 Mar 22;366(12):1079-89.

Lu, C, Ward, PS, Kapoor, GS, Rohle, D, Turcan, S, Abdel-Wahab, O, Edwards, CR,  Khanin, R, Figueroa, ME, Melnick, A, Wellen, KE, O’Rourke, DM, Berger, SL, Chan, TA, Levine, RL, Mellinghoff, IK, Thompson, CB. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012 Feb15;483(7390):474-8.

Betts, BC, Abdel-Wahab O, Curran SA, St Angelo ET, Koppikar P, Heller G, Levine RL, Young JW. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells, yet preserves immunity to recall antigen. Blood. 2011 Nov 10;118(19):5330-9.

Bejar, R, Stevenson, K, Abdel-Wahab, O, Galili, N, Nilsson, B, Garcia-Manero, G, Kantarjian, H, Raza, A, Levine, RL, Neuberg, D, and Ebert, B. Mutations in myelodysplastic syndromes are independent predictors of overall survival and are associated with clinical features. N Engl J Med. 2011 Jun 30;364(26):2496-506.

Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E, Liu C, Ibrahim S, Beran M, Zavadil J, Efstratiadis A, Taghon T, Michor F, Levine RL, Aifantis I. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011 May 12;473(7346):230-3.

Abdel-Wahab, O, Pardanani, A, Patel, J, Wadleigh, M, Lasho, T, Heguy, A, Beran, M, Gililland, DG, Levine, R, and Tefferi, A. Concomitant analysis of ASXL1 and EZH2 mutations in myelofibrosis, chronic myelomonocytic leukemia, and blast-phase myeloproliferative neoplasms. Leukemia. 2011 Jul;25(7):1200-2.

Figueroa ME, Abdel-Wahab O (Co-first author), Lu C (Co-first author), Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010 Dec 14;18(6):553-67.

Abdel-Wahab, O, Kilpivaara, O, Patel, J, Busque, L, Levine, RL. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia. 2010 Sep;24(9):1656-7.

Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010 Mar 16;17(3):225-34.

Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J , Hedvat C , Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Verstovsek S. Genetic analysis of leukemic transformation of chronic myeloproliferative neoplasms. Canc Res. 2010 Jan 15;70(2):447-52.

Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Jul 2;114(1):144-7.

Books, Book Chapters, and Reviews

Abdel-Wahab O, Figueroa ME. Interpreting new molecular genetics in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2012;2012:56-64. doi: 10.1182/asheducation-2012.1.56.

Chung YR, Schatoff E, Abdel-Wahab O. Epigenetic alterations in hematopoietic malignancies. Int J Hematol. 2012 Oct;96(4):413-27.

Shih AH, Abdel-Wahab O, Patel JP, Levine R.L. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012 Aug 14;22(2):180-93.

Abdel-Wahab O, Patel J, Levine RL. Clinical implications of novel mutations in epigenetic modifiers in AML. Hematol Oncol Clin North Am. 2011 Dec;25(6):1119-33.

Fathi A, Abdel-Wahab O. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol. 2012;2012:469592.

Abdel-Wahab O, Levine RL. EZH2 mutations: mutating the epigenetic machinery in myeloid malignancies. Cancer Cell. 2010 Aug 9;18(2):105-107.